- Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure.
- In case of patients who are not controlled on monotherapy like Amlodipine 5 mg and other lower dose combination drugs.
Dosage:
Dosage Modification:
- Renal Impairment
- Mild to moderate: Dose adjustment not required
- Severe: Initiate with lower dose combination; titrate slowly
- Hepatic Impairment
- Initiate with lower dose combination; titrate slowly
Telmisartan and Amlodipine tablets are contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan, amlodipine, or any other component of this product.
- Discontinue immediately with pregnancy; increased fetal/neonatal morbidity and mortality.
- May cause hypotension, particularly if volume or salt depleted (correct before initiating).
- Titrate slowly in patients with hepatic or severe renal impairment.
- ARBs (including Telmisartan) tend to raise the serum potassium level and reduce the glomerular filtration rate (GFR). Monitoring the serum potassium and creatinine levels and the GFR is therefore imperative. Hyperkalemia (increased potassium level) may be fatal in the elderly, in patients with renal insufficiency, in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels.
- Peripheral edema (1-11%)
- Dizziness (3%)
- Orthostatic hypotension (6%)
- Syncope (2%)
- Back pain (2%)
- Most common reported include headache, coughing, nausea, fatigue, upper respiratory tract infection, jaundice and hepatic enzyme elevations
- Store in cool and dry place.
